Lonza Capabilities Update March 2026: Cell & Gene Therapy

Joseph Garrity, Executive Director of Portfolio Management at Lonza, presents an in-depth overview of the organization’s capabilities in cell and gene therapy, mRNA, and microbial modalities. He highlights the company’s global scale, with decades of experience, a broad network of facilities, and a commitment to delivering end-to-end solutions from early development through commercial manufacturing. The session emphasizes the importance of integrating process development with GMP production to enable seamless tech transfer, scalability, and global supply. Garrity also outlines specialized expertise across autologous and allogeneic cell therapies, viral vectors, and mRNA platforms, supported by flexible infrastructure and a strong regulatory track record. With a focus on innovation, capacity expansion, and supply chain reliability, the presentation underscores how the organization partners with clients to accelerate advanced therapies and bring complex, life-changing treatments to patients worldwide.